TGTX TG Therapeutics Inc.

6.43
+0.01  (+0%)
Previous Close 6.42
Open 6.43
Price To Book 30.62
Market Cap 609,275,621
Shares 94,755,151
Volume 113,353
Short Ratio
Av. Daily Volume 1,016,794

NewsSee all news

  1. TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial

  2. TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that abstracts featuring ublituximab, the Company's novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing

  3. TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is incredibly saddened by

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced November 27, 2017.
TGR-1202 (umbralisib) plus obinutuzumab
Relapsing or refractory Follicular Lymphoma
Phase 2 long term follow up data presented at ECTRIMS, September 12, 2019.
TG-1101 (ublituximab)
Relapsing forms of Multiple Sclerosis (RMS)
Phase 3 data due in the middle to 2H 2020.
TG-1101 - ULTIMATE II
Multiple Sclerosis
Phase 1/2 updated data noted 91% ORR for CLL patients; 38% for Richter’s transformation.
Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in the middle to 2H 2020.
TG-1101 - ULTIMATE I
Multiple Sclerosis
NDA filing to be submitted by the end of 2019.
TG-1101 and TGR-1202 - UNITY-NHL study
Non-Hodgkin Lymphoma (NHL)
Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 PFS data due late 2019 or early 2020.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 1 updated data released at EHA June 2018. 2 patients (9%) achieved a durable complete remission.
TGR-1202
Myelofibrosis
Phase 1 trial initiation announced February 26, 2019.
TG-1801
Relapsed or Refractory B-cell Lymphoma

Latest News

  1. TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial

  2. TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that abstracts featuring ublituximab, the Company's novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing

  3. TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is incredibly saddened by